- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
- Interventions
- Alpha-1 MP
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 20 Years to 72 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- No Intervention
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Charleston, South Carolina
- Conditions
- Anxiety
- Interventions
- +Short AAT, +Long AAT, Active control; NO dog
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Fazirsiran Injection
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 5
- States / cities
- La Jolla, California • Redwood City, California • Gainesville, Florida + 2 more
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema
- Interventions
- SAR447537
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
- Conditions
- ST+ABR, ST+SHAM, ST-only
- Interventions
- ST+ABR, ST+Sham, ST Only
- Behavioral
- Lead sponsor
- University of Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas